Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (DMII) is a blank check special purpose acquisition company focused on the pharmaceutical and healthcare sector, with its stated investment thesis centered on domestic drug manufacturing businesses. The company filed its annual report on Form 10-K with the Securities and Exchange Commission on April 15, 2026, indicating it remains in its target-search phase. DMII is the second vehicle from its sponsor group, following the original Drugs Made In America Acquisition Corp., making it part of a serial SPAC program in the life sciences and pharmaceutical manufacturing space. Investors and analysts tracking DMII's deal timeline, SEC filings, and peer comparables can access full data by signing up at SpacDesk.